Skip to main content

Table 2 Outcome after 6 weeks and 3 months in BeSt for Kids study

From: A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study

  Arm 1
Sequential monotherapy
n = 32
Arm 2
Combo MTX + 6 wks prednisone
n = 32
Arm 3
Combo
MTX+ etanercept
n = 30
p
Inactive disease (%)* 6wks
3 mths
0 (0)
8 (25)
4 (13)
3 (9)
1 (3)
5 (17)
0.25
aACR Pedi 30 (%) 6 wks
3 mths
15 (47)
16 (50)
18 (56)
17 (53)
17 (57)
22 (73)
0.68
0.13
aACR Pedi 50 (%) 6wks
3 mths
9 (28)
10 (31)
14 (44)
12 (38)
11 (37)
16 (53)
0.56
0.19
aACR Pedi 70 (%) 6wks
3 mths
3 (9)
8 (25)
8(25)
6 (19)
6(20)
14 (47)
0.25
0.04
JADAS-10 (median) 6wks
3 mths
Δ JADAS-10 (median) 6wks
3 mths
13.9
9.0
3.2
6.9
9.6
11.5
6.6
5.7
12.4
8.2
5.0
10.2
0.12
0.25
0.012
0.22
  1. *according to our definition of inactive disease modified to Wallace 2004 definition: no active synovitis, no fever, rash, serositis, splenomegaly or generalized lymphadenopathy attributable to JIA. No active uveitis, ESR ≤ 16 mm/h and physician’s VAS <10 mm